ethyl 2-(5-bromo-2-methoxyphenyl)-2-oxoacetate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 2-(5-bromo-2-methoxyphenyl)-2-oxoacetate
• 化学式: C₁₁H₁₁BrO₄
• mdl: MFCD16061579
• 分子量: 287.11
• InChiKey: YJDSUIYWZQWSST-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 2-(5-bromo-2-methoxyphenyl)-2-oxoacetate 在 lithium hydroxide 、 sodium tetrahydroborate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 5-Bromo-2-methoxymandelic acid
  参考文献：
  名称：

  Lipophilic versus hydrogen-bonding effect in P3 on potency and selectivity of valine aspartyl ketones as caspase 3 inhibitors

  摘要：

  Caspase 3 is a cysteinyl protease that mediates apoptotic cell death. Its inhibition may have an important impact in the treatment of several degenerative diseases. The P, aspartic acid residue is a required element of recognition for this enzyme that was maintained constant along with the adjacent natural valine as the P-2 group. The thiobenzylmethylketone warhead on the aspartate was conveniently handled through solid-phase synthesis allowing modification in the P-3 region that eventually led to simpler derivatives with increased potency against caspase 3. The key to such an effect is the introduction of hydroxyl group alpha to the P3 carbonyl. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.05.116
• 作为产物：
  描述：

  4-溴苯甲醚 、 草酰氯单乙酯 在 aluminum (III) chloride 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以91%的产率得到ethyl 2-(5-bromo-2-methoxyphenyl)-2-oxoacetate
  参考文献：
  名称：

  [EN] ROR-GAMMA INHIBITORS
  [FR] INHIBITEURS DE ROR-GAMMA

  摘要：

  本发明涉及公式I的化合物和包含公式I化合物的药物组合物。公式I的化合物在治疗由RORγ介导的炎症性、代谢性或自身免疫性疾病方面是有用的。

  公开号：

  WO2019063748A1

文献信息

• [EN] ROR-GAMMA INHIBITORS<br/>[FR] INHIBITEURS DE ROR-GAMMA
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2019063748A1

  公开（公告）日：2019-04-04

  The present invention relates to compounds of formula I and pharmaceutical compositions comprising compounds of formula I. Compounds of Formula I are useful in treatment of inflammatory, metabolic or autoimmune diseases which are mediated by RORy.

  本发明涉及公式I的化合物和包含公式I化合物的药物组合物。公式I的化合物在治疗由RORγ介导的炎症性、代谢性或自身免疫性疾病方面是有用的。
• Lipophilic versus hydrogen-bonding effect in P3 on potency and selectivity of valine aspartyl ketones as caspase 3 inhibitors
  作者：Christophe Mellon、Reneé Aspiotis、Cameron W. Black、Christopher I. Bayly、Erich L. Grimm、André Giroux、Yongxin Han、Elise Isabel、Daniel J. McKay、Donald W. Nicholson、Dita M. Rasper、Sophie Roy、John Tam、Nancy A. Thornberry、John P. Vaillancourt、Steven Xanthoudakis、Robert Zamboni

  DOI：10.1016/j.bmcl.2005.05.116

  日期：2005.9

  Caspase 3 is a cysteinyl protease that mediates apoptotic cell death. Its inhibition may have an important impact in the treatment of several degenerative diseases. The P, aspartic acid residue is a required element of recognition for this enzyme that was maintained constant along with the adjacent natural valine as the P-2 group. The thiobenzylmethylketone warhead on the aspartate was conveniently handled through solid-phase synthesis allowing modification in the P-3 region that eventually led to simpler derivatives with increased potency against caspase 3. The key to such an effect is the introduction of hydroxyl group alpha to the P3 carbonyl. (c) 2005 Elsevier Ltd. All rights reserved.